Biggest News Aggregation in the World
📰 Oncologic Sciences News

Page 2 - Oncologic Sciences News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Oncologic Sciences. Real-time updates on events, politics, business and more.

Addition of Navitoclax to Dabrafenib/Trametinib Aims to Improve Efficacy of Targeted Therapy in BRAF+ Metastatic Melanoma

Zeynep Eroglu, MD, explains the rationale for adding navitoclax to dabrafenib plus trametinib in the treatment of patients with BRAF V600–mutant metastatic melanoma, highlights the methodologies and results of the CTEP-P9466 trial, and describes the implications of this research for this patient population.
United States Zeynep Eroglu Ryan Sullivan Department Of Oncologic Sciences Cutaneous Oncology Moffitt Cancer Center

Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
Medicine Oncologic Sciences Moffitt Cancer Center Experimental Therapeutics Program University Of South Florida Malignant Hematology Department College Of Medicine

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma

The combination of dabrafenib and trametinib plus navitoclax generated responses and met the co-primary end point for complete response rate vs historical controls in patients with BRAF V600–mutant metastatic melanoma.
United States Anita Giobbie Hurder Zeynep Eroglu Genentech Roche Boehringer Ingelheim Department Of Oncologic Sciences

Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.
United States Castle Biosciences Arthurg James Kari Kendra Iovance Biotherapeutics Department Of Oncologic Sciences

SAASCR Honors 10 Indian American Scientists for Their Outstanding Cancer Research

The Society of Asian American Scientists in Cancer Research April 11 announced that it has honored 10 Indian American scientists for their outstanding cancer research. Dr. Rajvir Dahiya, professor emeritus at U.C. San Francisco’s School of Medicine and president of SAASCR, presented awards to these scientists April 11 during the American Association for Cancer Research annual meeting, according to the news release. The awardees were Drs. Zaver M. Bhujwalla, Pankaj K. Singh, Neil Bhowmick, ...
University Of California Los Angeles United States Uttar Pradesh University Of South Florida San Diego San Francisco

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science